Cabaletta Bio reports smaller-than-expected Q3 loss

Cabaletta Bio

10/11/2025 12:42

Overview

Company advancing rese-cel clinical trials with promising data for autoimmune diseases

Cabaletta expects cash reserves to fund operations into the second half of 2026

Outlook

Cabaletta plans BLA submission for rese-cel in 2027

Company expects FDA alignment on cohort designs by end of 2025

Cabaletta anticipates enrollment in registrational cohorts in 2026

Result Drivers

Research and development expenses were $39.8 million for the three months ended September 30, 2025, compared to $26.3 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Beat
-$44.87 mln
-$45.55 mln (6 Analysts)
Q3 Income from Operations
-$46.59 mln
Q3 Operating Expenses
$46.59 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cabaletta Bio Inc is $14.50, about 82.4% above its November 7 closing price of $2.55

Press Release: ID:nGNX527bsD

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)